Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 1477Neoplasms 999Colorectal Neoplasms 832Carcinoma, Non-Small-Cell Lung 724Carcinoma, Hepatocellular 683Stomach Neoplasms 648Lung Neoplasms 584Prostatic Neoplasms 543Pancreatic Neoplasms 456Rectal Neoplasms 339Uterine Cervical Neoplasms 303Colonic Neoplasms 295Neoplasm Metastasis 294Ovarian Neoplasms 285Esophageal Neoplasms 279Recurrence 278Leukemia, Myeloid, Acute 253Head and Neck Neoplasms 241Multiple Myeloma 232Brain Neoplasms 204Polycystic Ovary Syndrome 200Nasopharyngeal Carcinoma 198Melanoma 198Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Urinary Bladder Neoplasms 193Lymphoma 178Liver Neoplasms 178Endometrial Neoplasms 159Motor Activity 147Lymphoma, Large B-Cell, Diffuse 141

Interventions

camrelizumab 2apatinib 2S 1 (combination) 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × Metastatic Gastric Adenocarcinoma × Clear all
NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡